Chemomab Therapeutics (CMMB)

• Market cap: $10.2M
• 1 day: -2.35%
• 5 days: -7.78%
• 1 month: -19.42%
• 3 months: -49.39%
• 6 months: -63.6%
• Year to date: -7.26%
• 1 year: -78.72%
• 5 years: -98.76%
• 10 years: -99.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Employees: 16